TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Since a few years, STI571 (Imatinib mesylate; Gleevec), a specific Bcr-Abl tyrosine kinase (TK) inhibitor, has profoundly modified the therapeutic approach of CML and created a big emphasis on development of specific TK inhibitors [2].